Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Alessandro Casini1, Hanny Al-Samkari2, Catherine Hayward3

  • 1Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine of Geneva, Geneva, Switzerland.

Haemophilia : the official journal of the World Federation of Hemophilia
|March 18, 2024
PubMed
概括
此摘要是机器生成的。

罕见出血障碍 (RBDs) 的管理仍然具有挑战性,除了因子替代之外,治疗选择有限. 需要进一步的研究,以优化治疗遗传性纤维素因子疾病,血小板功能障碍和遗传性出血性远程切除症的疗法.

关键词:
纤维激素缺乏症 纤维激素缺乏症遗传性出血性远程切除术 (telangiectasia) 是一种遗传性出血性远程切除术.遗传性血小板功能障碍 遗传性血小板功能障碍罕见的出血障碍 罕见的出血障碍

相关实验视频

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Patients with hereditary hemorrhagic telangiectasia have significantly reduced overall survival-And likely by a greater magnitude than we realize.

Journal of internal medicine·2026
Same author

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome.

American journal of hematology·2026
Same author

A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders.

Expert review of hematology·2026
Same author

Mitapivat for sickle cell disease: the time is ripe for a new therapy.

Annals of translational medicine·2026
Same author

Case 14-2026: A 50-Year-Old Woman with Vaginal Bleeding and Anemia.

The New England journal of medicine·2026
Same author

Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.

Journal of clinical medicine·2026
Same journal

Male Range of Motion Norms in the Haemophilia Joint Health Score Underrepresent the Severity of Joint Damage in Females.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Physical Activity and Sedentary Behaviour in Children With Haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Ten-year Demographic and Clinical Characterisation of People With Haemophilia: The Colombian Registry Experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Exploratory Claims-Based Assessment of Diagnosed and Potentially Undiagnosed von Willebrand Disease in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Use of an Oral Health-Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
查看所有相关文章

科学领域:

  • 血液学 血液学 血液学
  • 罕见疾病 罕见疾病
  • 血管医学 血管医学

背景情况:

  • 罕见的出血障碍 (RBDs),包括遗传性纤维素因子障碍,遗传性血小板功能障碍 (IPFD) 和遗传性出血端膜病 (HHT),呈现出各种出血严重程度.
  • 虽然对RBD的知识有所进步,但治疗管理策略仍然有限且具有挑战性.

研究的目的:

  • 审查目前罕见出血障碍的管理状况.
  • 确定未来研究的关键挑战和领域,以优化RBDs的治疗.

主要方法:

  • 文献综述侧重于流行病学,遗传学,病理生理学,临床特征,诊断和RBDs的管理.
  • 分析当前治疗的主要支柱和新兴的治疗策略.

主要成果:

  • 目前的治疗依赖于因子替代,对前凝和抗凝剂越来越感兴趣.
  • 关于IPFD的最佳策略,非基因血症中的纤维素替代和HHT治疗存在重大不确定性.
  • 在RBD中使用德斯莫普林素,抗纤维解压剂和抗血管原剂的数据需要进一步研究其有效性和安全性.

结论:

  • 经管RBDs需要显著的改进超出目前的替代疗法.
  • 进一步的研究对于确定各种RBD的新型和现有治疗方法的最佳剂量,安全性和疗效至关重要.